HuMax-TAC™ is a human antibody that targets the TAC antigen, also known as CD25 or the interleukin-2 receptor alpha subunit (IL-2Ra), which is over-expressed by activated T-cells. By inhibiting the proliferation of T-cells, HuMax-TAC may have therapeutic potential in the treatment of T-cell mediated diseases, such as autoimmune disorders, inflammatory and hyperproliferative skin disorders, as well as acute transplant rejection. 

Selected Scientific References:

Bielekova, B., N. Richert, T. Howard, G. Blevins, S. Markovic-Plese, J. McCartin, J.A. Frank, J. Wurfel, J. Ohayon, T. Waldmann, H.F. McFarland and R. Martin. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. PNAS 2004; 101(23): 8705-8708.

Kapic, E., F. Becic and J. Kusturica. Basiliximab, mechanism of action and pharmacological properties. Med Arh 2004; 58(6), 373-376.

Morris, J.C. and T.A. Waldmann. Advances in interleuking 2 receptor targeted treatment. Ann Rheum Dis 2000; 59(suppl. I): i109-i114.